Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
09:01am, Thursday, 05'th Oct 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
12:45pm, Thursday, 03'rd Aug 2023
Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics
11:13pm, Wednesday, 02'nd Aug 2023
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
08:23am, Thursday, 20'th Jul 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease
02:22pm, Wednesday, 19'th Jul 2023
Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.
These 2 Soaring Stocks Finished the Week Strong
06:22pm, Friday, 14'th Jul 2023
Some markets gave up their early gains on Friday but still were higher for the week. Aehr Test Systems expects a strong year in fiscal 2024.
Glaukos (GKOS) Stock Hits 52-Week High: More Room to Grow?
09:39am, Friday, 14'th Jul 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos: Revising To Buy On These 3 Catalytic Factors
06:13am, Friday, 16'th Jun 2023
Glaukos Corporation has 3 catalysts to price change going forward. These involve the company's performance, growth, and potential future developments. Revising to buy on fundamental, sentimental groun
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
10:43am, Friday, 19'th May 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y
08:22am, Thursday, 04'th May 2023
Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.
Glaukos Corporation (GKOS) Q1 2023 Earnings Call Transcript
10:53pm, Wednesday, 03'rd May 2023
Glaukos Corporation (NYSE:GKOS ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Chris Lewis – Vice President-Investor Relations and Corporate Affairs Tom Burns – Chai
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
08:32pm, Wednesday, 03'rd May 2023
Glaukos (GKOS) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.38 per share a year ago.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
12:55pm, Monday, 03'rd Apr 2023
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Q4 Earnings Beat Estimates, Sales Decline Y/Y
12:03pm, Thursday, 23'rd Feb 2023
Glaukos' (GKOS) Q4 revenues beat estimates but fall year over year. Lower revenues, along with higher expenses, hurt margins.
Glaukos Corporation (GKOS) Q4 2022 Earnings Call Transcript
09:02pm, Wednesday, 22'nd Feb 2023
Glaukos Corporation (NYSE:GKOS ) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Chris Lewis – Vice President-Investor Relations and Corporate Affairs Tom Burns �
